1                                              GlyT-1 inhibitors elevate extracellular glycine and thus

2 ing treatments of the glycine transporter-1 (GlyT-1) inhibitor, Org24598, with extinction training on

3 nzamide inhibitors of glycine transporter-1 (GlyT-1), represented by analogues 10 and 11.

4 h [3H]glycine via the glycine transporter-1 (GlyT-1), which localized to the cholinergic presynaptic

5 ut lack expression of glycine transporter-1 (GlyT-1).

6  ketamine and did so optimally in the 40-70% GlyT-1 occupancy range.

7 elationship between occupancy of GlyT-1 by a GlyT-1 inhibitor, Org 25935, and its impact on spatial w

8 Org 25935 had no effect on working memory at GlyT-1 occupancies lower than 75% and significantly impa

9 r positive valence deficit was attenuated by GlyT-1 treatment, suggesting that these and the attentio

10                                    The glial GlyT subtype GlyT1 is well located to activate NMDA rece

11                               However, glial GlyTs have not been studied in an intact system thus far

12                                  These glial GlyTs can probably mediate glycine efflux under conditio

13 antify the relationship between occupancy of GlyT-1 by a GlyT-1 inhibitor, Org 25935, and its impact

14 ts support the potential clinical utility of GlyT-1 inhibitor pretreatments combined with cocaine-cue

15 nt studies provide support that personalized GlyT-1 inhibition may treat attentional deficits in neur

16           Glycine is actively cleared by the GlyT expressed within beta-cells, which store and releas

17 t was calcium independent and blocked by the GlyT-1 inhibitor sarcosine.

18 as attenuated by glycine type-1 transporter (GlyT-1) inhibition.

19 alpha1 subunit, and the glycine transporter (GlyT) isoforms GlyT1 and GlyT2.

20 xylase (GAD)-67 mRNA or glycine transporter (GlyT)-2 mRNA detected with in situ hybridization (ISH).

21 orebrain by the glycine type-1 transporters (GlyT-1).

22  Na(+)/Cl(-)-dependent glycine transporters (GlyTs) in neurones and glia.

23 ng a desirable balance of excellent in vitro GlyT-1 potency and selectivity, favorable ADME and in vi